Cue Biopharma spotlights durable CSU response as CUE-221 holds benefit 12 weeks after last dose
Market Chameleon (Mon, 21-Sep 11:02 AM)
Cue Biopharma’s CUE-221 posts statistically significant Phase 2 CSU results, with Week 28 separation versus omalizumab
Market Chameleon (Mon, 21-Sep 7:05 AM)
